<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01913652</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1202</org_study_id>
    <secondary_id>2012-003672-39</secondary_id>
    <secondary_id>cabazL06470</secondary_id>
    <nct_id>NCT01913652</nct_id>
  </id_info>
  <brief_title>Ph II Cabazitaxel DD Liposarcoma</brief_title>
  <official_title>Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (&gt; 50&#xD;
      histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct&#xD;
      genetic, pathological and clinical profiles, and varying patterns of tumor spread. The&#xD;
      optimal cytotoxic treatment for this group of patients remains uncertain. Single agents which&#xD;
      are most effective include doxorubicin and ifosfamide, but objective response rates and&#xD;
      progression-free survival times remain modest. There is clearly a need to improve treatment&#xD;
      options for liposarcoma. Eribulin, a antimicrotubule agent that targets the protein tubulin&#xD;
      in cells, interfering with cancer cell division and growth , has demonstrated activity in&#xD;
      STS. Therefore, it is reasonable to explore whether other anti-microtubule agent like&#xD;
      cabazitaxel have a role in STS. Cabazitaxel has been shown to be a relatively safe, effective&#xD;
      and tolerated. This drug has been approved by FDA for prostate cancer. The main objective of&#xD;
      this trial is to determine whether cabazitaxel demonstrate sufficient antitumor activity for&#xD;
      liposarcoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>The primary endpoint will be progression free survival, assessed at 12 weeks after start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>Objective tumor response as defined by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of response</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>Time to onset of response will be measured for patients achieving an objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>Duration of response will be measured for patients achieving an objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of adverse events</measure>
    <time_frame>3 years from first patient in</time_frame>
    <description>This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Dedifferentiated Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INN: Cabazitaxel Cabazitaxel will be administered at a dose of 25 mg/m² by intravenous infusion, over 1 hour, on day 1 of each 21 day cycle.&#xD;
Treatment should be administered until disease progression, unacceptable toxicity or patient's refusal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Local diagnosis of dedifferentiated liposarcoma&#xD;
&#xD;
          -  Age 18-75 yrs&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Radiological or histological diagnosis of inoperable locally advanced or metastatic&#xD;
             disease, with evidence of disease progression within the past 6 months&#xD;
&#xD;
          -  Clinically and/or radiographically documented measurable disease within 21 days prior&#xD;
             to randomization.At least one site of disease must be unidimensionally measurable&#xD;
             according to RECIST 1.1.&#xD;
&#xD;
          -  One previous chemotherapy regimen for locally advanced or metastatic dedifferentiated&#xD;
             liposarcoma (this could include pre-operative chemotherapy for primary disease if&#xD;
             subsequent complete resection was not achieved).&#xD;
&#xD;
          -  Adequate haematological, renal and hepatic function&#xD;
&#xD;
          -  Birth control measures&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months&#xD;
&#xD;
          -  Related adverse events from previous therapies ≤ Grade 1&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 1 prior molecularly targeted therapy (e.g. CDK4 inhibitor). Any prior such&#xD;
             therapy must be completed at least 4 weeks before randomization.&#xD;
&#xD;
          -  Symptomatic CNS metastases&#xD;
&#xD;
          -  Previous encephalopathy of any cause or other significant neurological condition&#xD;
&#xD;
          -  Concurrent or planned treatment with strong inhibitors or inducers of cytochrome P450&#xD;
             3A4/5&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  inflammation of the urinary bladder (cystitis)&#xD;
&#xD;
          -  Other invasive malignancy within 5 years (exceptions of non-melanoma skin cancer,&#xD;
             localized cervical cancer, localized and presumably cured prostate cancer or&#xD;
             adequately treated basal or squamous cell skin carcinoma)&#xD;
&#xD;
          -  Significant cardiac disease&#xD;
&#xD;
          -  Uncontrolled severe illness or medical condition, other than DD liposarcoma&#xD;
&#xD;
          -  Hypersensitivity to taxanes or their excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Hayward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western General Hospital, Edinburgh, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen (117)</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet (101)</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Centre Georges-Francois-Leclerc (229)</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard (227)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone (287)</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori (704)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS - Ospedale Busonera (3908)</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology NHS Trust - Clatterbridge Cancer Centre NHS Foundation Trust (659)</name>
      <address>
        <city>Bebington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Chelsea, London (613)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust (610)</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dedifferentiated liposarcoma</keyword>
  <keyword>cabazitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

